<Record>
<Term>Atiprimod</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Signal Transduction Inhibitor</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Antineoplastic Agent/Signal Transduction Inhibitor/Atiprimod</ClassificationPath>
<BroaderTerm>Signal Transduction Inhibitor</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Antineoplastic Agent</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Atiprimod</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Atiprimod</Synonym>
<Synonym>Azaspirane SK&amp;amp;F106615</Synonym>
<Synonym>N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine</Synonym>
<Synonym>SK&amp;amp;F106615</Synonym>
<Description>An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.</Description>
<Source>NCI Thesaurus</Source>
</Record>
